Zydus Lifesciences Limited has informed the Exchange regarding a press release dated May 09, 2024, titled "Zydus Announces Completion of Enrolment for EPICS IIITM Phase 2b/3 trial evaluating Saroglitazar Mg in treatment of Primary Biliary Cholangitis".
Press Release May 09 2024
Filed with NSE · · 5 pages · English
Summary by 6ix AI
This trial aims to assess the efficacy and safety of Saroglitazar Mg in patients who are not adequately controlled on standard first-line treatments. The announcement highlights the importance of new treatment options for patients suffering from this rare liver disease.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Zydus Lifesciences Limited on 6ix
Earlier from Zydus Lifesciences
- Press Release May 04 2024
- Press Release Apr 26 2024
- Press Release Apr 23 2024
- Press Release Apr 22 2024
- Press Release Apr 20 2024
Later from Zydus Lifesciences
- Press Release May 11 2024
- Zydus Lifesciences Limited Press Release May 17 2024
- Press Release May 22 2024
- Press Release May 24 2024
- Press Release Jun 14 2024
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences